Evidence map›Paper›PMID 24389146›Full record

ReviewFrontiers in bioscience (Elite edition)2014

Polycystic ovary syndrome: current status and future perspective.

Erin K Barthelmess, Rajesh K Naz

Registry-linked trialOpen access · bronzeAbstract readReview
In one paragraph

Review in Frontiers in bioscience (Elite edition), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03151005 (Randomized Clinical Trial to Evaluate The Effect of Metformin-GLP-1 Receptor Agonist Versus Oral Contraceptive), which is not on this map. Cited by 98 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
98citing papers in PubMed, 1 pooled it
11.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03151005 phase4completedstarted 2017, after this paper: background citation

Randomized Clinical Trial to Evaluate The Effect of Metformin-GLP-1 Receptor Agonist Versus Oral Contraceptive (OC) Therapy on Reproductive Disorders and Cardiovascular Risks in Overweight Polycystic Ovarian Syndrome (PCOS) Patients

Ran2017Enrolled70Registered outcomes5Posted comparisons0ConditionsObesity, Overweight, Polycystic Ovary Syndrome (PCOS)ArmsMetformin-GLP-1 Receptor Agonist, Metformin-Oral Contraceptive(OC)
Open the trial in the graph
3 · Its place in the literature

Who cites it

98 citing papers in PubMed, 1 synthesis or guideline pooled it, 248 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Polycystic Ovary Syndrome Revisited: Novel Insights and Updates.International journal of medical sciences · 2026
    Review
  11. Article
  12. Review
  13. Observational
  14. Review
  15. Review
  16. Article
  17. Observational
  18. Article
  19. Article
  20. Article

38 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Erin K BarthelmessReproductive Immunology and Molecular Biology Lab, Department of Obstetrics and Gynecology, West Virginia University School of Medicine, Health Sciences Center, Morgantown, WV 26506-9186.
Rajesh K NazReproductive Immunology and Molecular Biology Lab, Department of Obstetrics and Gynecology, West Virginia University School of Medicine, Health Sciences Center, Morgantown, WV 26506-9186.
West Virginia University · US

Funding

West Virginia IDEA-CTRU54GM104942 · NIGMS · WEST VIRGINIA UNIVERSITY · PI Sijin Wen · 2012 to 2026
$81.0M
NIGMS NIH HHS U54 GM104942NIGMS NIH HHS U54GM104942
6 · The paper itself

Abstract

Polycystic ovary syndrome (PCOS) is a widespread reproductive disorder that encompasses many associated health conditions and has an impact on various metabolic processes. PCOS is depicted by hyperandrogenism, polycystic ovaries, and anovulation. It increases the risk of insulin resistance (IR), type 2 diabetes, obesity, and cardiovascular disease. The etiology of the disease remains unclear, and the subjective phenotype makes a united diagnosis difficult among physicians. It seems to be a familial genetic syndrome caused by a combination of environmental and genetic factors. It can be linked with metabolic disorders in first-degree family members. PCOS is the cause of up to 30% of infertility in couples seeking treatment. Currently, there is no cure for PCOS. Despite the growing incidence of this syndrome, limited research has been done that encompasses the entirety of PCOS spectrum. In this review, the current status and possible future perspective will be discussed.

Indexed as

Disease ManagementAndrogensFemaleHumansHyperandrogenismInfertility, FemaleInsulin ResistanceLaparoscopyMetforminObesityPolycystic Ovary SyndromePubMedResearchAndrogensMetformin

Identifiers

PMID24389146
PMCPMC4341818
OpenAlexW2062130408

What OpenQuestion holds

Texttitle and abstract
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.